FDA clears TyRx' PIVIT AB antimicrobial-coated surgical mesh:
This article was originally published in Clinica
Executive Summary
TyRx Pharma has received US FDA 510(k) clearance to sell an antimicrobial-coated version of its PIVIT surgical mesh. PIVIT AB not only improves patient comfort, as with the earlier device, it also reduces bacterial colonisation of the product during its implantation. It is coated with a bioresorbable polymer containing rifampin and minocycline; the antimicrobial-free version of the device was cleared for sale last year. The Monmouth Junction, New Jersey firm says that its products leave less implant material in the body following the resorption of the bioresorbable polymer coating, a property that is expected to help facilitate patient comfort during the post-operative period and beyond. PIVIT AB is indicated for repairing hernias and other abdominal fascial deficiencies.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.